stockrowBillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) EV/EBITDA
As of 5 November 2026, BillionToOne, Inc. (BLLN) trades at a EV/EBITDA of 86.7×. Over the past ten years it has ranged from 20.7× (March 2026) to 608× (November 2025); the current reading is higher than 65% of that period. That is above the Diagnostics & Research industry median of 23.4× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 30.8× | (93.80%) |
| FY2024 | 497× | 0.00% |
| FY2023 | 497× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 82.0× | (10.78%) |
| Jun 2026 | 91.9× | 38.95% |
| Mar 2026 | 66.1× | 114.60% |
| Dec 2025 | 30.8× | (93.80%) |
| 4 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| GRAL GRAIL, Inc. compare | n/m |
| ADPT Adaptive Biotechnologies Corporation compare | n/m |
| VCYT Veracyte, Inc. compare | 11.8× |
| SHC Sotera Health Company compare | 11.9× |
| QGEN QIAGEN N.V. compare | 17.4× |
| RDNT RadNet, Inc. compare | 21.8× |
| CDNA CareDx, Inc. compare | 26.6× |
| BLLN BillionToOne, Inc. | 86.7× |
| NEO NeoGenomics, Inc. compare | 147× |
| Diagnostics & Research industry median | 23.4× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement